Herpesvirus Infection May Increase the Risk of Developing Diabetes
By LabMedica International staff writers Posted on 30 May 2022 |
Type 2 diabetes (T2D) is one of the most widespread metabolic diseases, with a 2019 worldwide prevalence estimate of 9.3%, exerting a high mortality burden mainly due to cardiovascular disease.
Herpesviruses are one of the most prevalent viruses in humans, with eight types currently known: herpes simplex viruses (HSV) 1 and 2, varicella-zoster virus (VZV), Epstein-Barr virus (EBV), cytomegalovirus (CMV) and human herpesviruses (HHV) 6, 7 and 8. All of them cause lifelong latent infections in their hosts after an initial, usually mild or asymptomatic primary infection.
Medical Scientists at the Ludwig-Maximilians University (Munich, Germany) and their colleagues included in a study group, 962 (49%) men and 999 (51%) women who had had a median age of 54 years at baseline. Incidence analysis for the development of (pre)diabetes used the data for those 1,257 participants with normal glucose tolerance at baseline (median age 49 years, 42% male and 58% female [528 and 729 individuals, respectively]).
Participants with no prior diagnosis of T2D underwent a standard oral glucose tolerance tests (OGTT) with diabetes status assigned using recommended thresholds and measurement of glycated hemoglobin (HbA1c) (a measure of blood sugar control over the previous 3 months). Human herpesvirus serology was determined using multiplex serology, a suspension array-based immunoassay based on recombinant herpesvirus antigens bound to fluorescence-encoded microspheres. Measurements were performed on a Luminex 100 Total System comprising the Luminex 100 analyzer, Luminex XYP plate handler, Luminex SD sheath fluid delivery system (Luminex, Austin, TX, USA).
The investigators reported that the prevalence of prediabetes (impaired fasting glucose [IFG] and impaired glucose tolerance [IGT]) was 27.5% at baseline and 36.2% at follow-up, while T2D was present in 8.5% of participants at baseline and 14.6% at follow-up. Blood testing at the beginning of the study found that EBV was the most prevalent herpesvirus with 98% of the sample group being seropositive, followed by HSV1 (88%), HHV7 (85%), VZV (79%), CMV (46%), HHV6 (39%) and HSV2 (11%). Around one third (34%) tested positive for more viruses at the end of the follow-up period, 54% had the same number, and only 12% were positive for fewer viruses than at the start.
Of the seven herpesviruses examined, HSV2 and CMV were associated with incidence of (pre)diabetes among individuals with normal glucose tolerance at baseline that were independent of other risk factors. Individuals with HSV2 were 59% more likely to develop (pre)diabetes than those who were seronegative, while CMV infection was associated with a 33% increased (pre)diabetes incidence.
The authors concluded that multiplex serology may replace standard ELISA technology, particularly for epidemiologic settings. Applications beyond epidemiology could be the monitoring of infections during pregnancy and the differential diagnosis of infections with similar clinical symptoms. The study was published on May 11, 2022 in the journal Diabetologia.
Related Links:
Ludwig-Maximilians University
Luminex
Latest Microbiology News
- Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases
- Clinical Decision Support Software a Game-Changer in Antimicrobial Resistance Battle
- New CE-Marked Hepatitis Assays to Help Diagnose Infections Earlier
- 1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens
- Mouth Bacteria Test Could Predict Colon Cancer Progression
- Unique Metabolic Signature Could Enable Sepsis Diagnosis within One Hour of Blood Collection
- Groundbreaking Diagnostic Platform Provides AST Results With Unprecedented Speed
- Simple Blood Test Combined With Personalized Risk Model Improves Sepsis Diagnosis
- Blood Analysis Predicts Sepsis and Organ Failure in Children
- TB Blood Test Could Detect Millions of Silent Spreaders
- New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours
- New Tuberculosis Test to Expand Testing Access in Low- and Middle-Income Countries
- Rapid Test Diagnoses Tropical Disease within Hours for Faster Antibiotics Treatment
- Rapid Molecular Testing Enables Faster, More Targeted Antibiotic Treatment for Pneumonia
- Rapid AST Platform Provides Targeted Therapeutic Results Days Faster Than Current Standard of Care
- New Analysis Method Detects Pathogens in Blood Faster and More Accurately by Melting DNA